Ìý Laurent Legault, M.D. Associate professor, Department of Pediatrics, Division of Endocrinology Tel: 514-412-4400 ext. 24436 laurent.legault [at] muhc.mcgill.ca |
Biographical Sketch
Dr. Legault is an Associate Professor specializing in endocrinology in the Department of Paediatrics at ºÚÁϲ»´òìÈ University and was head of the Diabetes Clinic from (2000 to 2011) and (2014-2020). He is currently head of that division. He specializes in clinical endocrinology and metabolism. The Diabetes Clinic treats over 700 youth with type 1 diabetes, 40% of which are on insulin pump therapy. Dr. Legault is recognized in Canada for his clinical work on children with type 1 diabetes and his pioneering role in the use of insulin pumps in Quebec. He was the first medical director of the Montreal Children's hospital's insulin pump centre, opened in 2005, a freestanding centre dedicated to the teaching of families and management of children on insulin pump therapy. The pump centre has, through the leadership of its team, successfully mentored both pediatric and adult diabetes clinics to get their own pump clinics started as well as strives to improve knowledge in this rapidly evolving field. He was one of the leaders of a government mandated pilot project on the implementation of a provincial wide government sponsored pediatric insulin pump program. Dr. Legault has been involved as a PI in multicentre trials looking at prevention of type 1 diabetes (CanEndit, Trigr) and has been involved in exercise-based interventions in the field of pediatric obesity and spearheaded a community-based program on exercise and health for obese children in a low socio-economic neighborhood in the Montreal area. He is actively involved in the development of a closed loop (aka artificial pancreas) system since 2009 in collaboration with Dr. Ahmad Haidar, PhD.
Keywords
Artificial pancreas, diabetes and exercise, pediatric obesity and T2diabetes, prevention of type 1
Research or Clinical Activities
Since 2009, development of a dual hormone closed loop system in collaboration with Dr. Remi Rabasa-Lhoret (IRCM) and Ahmad haidar phD (RCM).
Involved in several multicentre trials looking at:
·ÌýÌýÌýÌýÌýÌý T1 DM prevention (Trigr)Ìý
·ÌýÌýÌýÌýÌýÌý Best practice for pediatric obesity guidance and treatment delivery (CanPwr, SISOSIG)
·ÌýÌýÌýÌýÌýÌý Impact of OSA treatment on metabolic profile (IMPACT study)
·ÌýÌýÌýÌýÌýÌý Metabolic impact on infants of treatment of gestational diabetes with Metformin (Mitykids study). Ìý
Selected Recent Publications
Haidar A, Legault L, Dallaire M , Alkhateeb A, Coriati A, Messier V, Cheng P, Millette M, Boulet B and Rabasa-Lhoret R, Glucose-Responsive Insulin and Glucagon ÌýDelivery to Regulate Glucose Levels in Adults with Type 1 Diabetes: Randomized Crossover Controlled Trial, CMAJ, 2013, 185:297-305.
Haidar A, Legault L, Dallaire M , Alkhateeb A, Coriati A, Messier V and Rabasa-Lhoret R, Comparison of continuous subcutaneous insulin infusion, single-hormone artificial pancreas, and dual-hormone artificial pancreas for glycaemic control in type 1 diabetes: a randomized controlled crossover trial, Lancet Diabetes Endocrinol. 2014 vol 3, 17-26.
Haidar A, Legault L, Matteau-Pelletier L, Messier V, Dallaire M, Ladouceur M andÌý Rabasa-Lhoret R, Outpatient Overnight Glucose Control with Dual- and Single-hormone Artificial Pancreas Systems in Children and Adolescents with Type 1 Diabetes, Lancet Diabetes Endocrinol Ìý2015, Vol. 3,ÌýNo. 8,Ìýp595–604.
A Haidar, R Rabasa-Lhoret, L Legault, LE. Lovblom, R Rakheja, V Messier, É D'Aoust, CM Falappa, T Justice, A Orszag, H Tschirhart, M Dallaire, M Ladouceur and BA. Perkins , Single- and Dual-hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes, Journal of Clinical Endocrinology & Metabolism, 2016,101(01): 214-221.
Taleb N, Emami A, Suppere C, Messier V, Legault L, Ladouceur M, Chiasson JL, Haidar A, Rabasa-Lhoret R, Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial. Diabetologia 2016 Dec; 59(12): 2561-2571.